Delcath Systems (DCTH) vs electroCore (ECOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
electroCore (ECOR) has outperformed Delcath Systems (DCTH) over the past year, gaining 84.7% versus a gain of 35.5%. Over five years, DCTH leads with a +59.8% price change compared with -36.4% for ECOR. Delcath Systems is the larger company by market cap ($521.9 million vs $85.7 million), about 6.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DCTH | ECOR |
|---|---|---|
| Share price | $15.04 | $9.51 |
| Market cap | $521.87M | $85.74M |
| 1-day change | -2.21% | -2.16% |
| YTD return | +48.91% | +112.04% |
| 1-year return | +35.50% | +84.66% |
| 5-year return | +59.83% | -36.41% |
| Forward P/E | 334.22 | — |
| EPS (TTM) | $0.01 | $-1.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.42 | $12.70 |
| 52-week low | $8.12 | $4.41 |
| Distance from 52-week high | -13.66% | -25.12% |
| Analyst consensus | none | none |
| Avg. price target upside | +59.57% | +101.58% |
| Average volume | 479.73K | 80.51K |
| Shares outstanding | 34.70M | 9.02M |
| Employees | 156 | 83 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Delcath Systems is about 6.1 times larger than electroCore by market value ($521.87M vs $85.74M).
- ECOR has outperformed DCTH by 49.2 percentage points over the past year.
About Delcath Systems
DCTH stock →Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Healthcare · Medical Devices · 156 employees
About electroCore
ECOR stock →electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Healthcare · Medical Devices · 83 employees
DCTH vs ECOR FAQ
Which is bigger, Delcath Systems or electroCore?
Delcath Systems (DCTH) is larger, with a market capitalization of $521.87M compared with $85.74M for electroCore (ECOR).
Which stock has performed better over the past year, DCTH or ECOR?
ECOR returned +84.66% over the past 12 months, compared with +35.50% for DCTH (price return, excluding dividends). Past performance does not predict future results.
Are Delcath Systems and electroCore in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.